Jacobio Pharmaceuticals Group Co., Ltd.
加科思藥業集團有限公司

21 DEC 2020

JACOBIO PHARMACEUTICALS GROUP CO., LTD. is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of innovative oncology therapies. The Company is an explorer in developing clinical-stage small-molecule drug candidates to modulate enzymes by binding to their allosteric sites, in order to address targets which are lack of easy-to-drug pockets where drugs can bind. Leveraging its proprietary technologies and know-how in drug discovery and development, the Company have discovered and developed an innovative pipeline of drug candidates. With two clinical-stage theSHP2 inhibitor and a leading KRAS inhibitor, its rich pipeline also includes several early-stage drug candidates that target a variety of other major and critical pathways, and may be among the first few market entrants in their respective drug classes globally. The Company will proactively enter into strategic and synergistic partnerships with leading MNCs, while establishing manufacturing and commercialisation capabilities in China to develop innovative cancer therapies to capture global market opportunities and treat cancer patients globally.

加科思藥業集團有限公司是一家臨床階段製藥公司，專注於創新腫瘤療法的自主發現和開發。公司在開發臨床階段小分子候選藥物方面是探索者。通過結合變構位點來調節酶以應對缺少容易成藥且允許藥物結合的口袋的靶點。加科思藥業憑藉在藥物發現及開發方面的專利技術及專業技術發現及開發創新在研候選藥物，公司擁有兩個臨床階段的SHP2抑制劑項目以及領先的KRAS抑制劑項目，其豐富的在研項目亦包括處於早期階段的靶向多種其他關鍵信號通路的候選藥物，可能成為全球該等相應藥物類別中首批進入市場的產品之一。加科思藥業目前已與AbbVie達成戰略合作，全球化發展和商業化SHP2抑制劑，公司將繼續積極與領先跨國公司合作，同時在中國設立製造和商業化能力，抓住全球市場機遇，為全世界癌症患者提供有效的創新療法。